Stereoselective neuroimaging in vivo

European Neuropsychopharmacology

Volumn 17, Issue 8, 2007, Pages 507-522

  Smith, Donald F ^a   Jakobsen, Steen ^b  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Brain imaging; Neuroreceptor ligands; PET; Pharmacokinetics; Positron emission tomography; Radiolabeled enantiomers; Receptor; Single photon emission tomography; SPECT; Stereoselective neurotransmission

Indexed keywords

1,2,3,5,6,10BETA HEXAHYDRO 6 [4 (METHYTHIO)PHENYL]PYRROLO[2,1 A]ISOQUINOLINE C 11; 1,2,3,5,6,10BETA HEXAHYDRO 6 [4 (METHYTHIO)PHENYL]PYRROLO[2,1 A]ISOQUINOLINE F 18; 2 [(2 METHOXYPHENOXY)PHENYLMETHYL]MORPHOLINE C 11; 2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL)TROPANE I 123; 3 (4 FLUORONAPHTHYL) 1 (N METHYLPIPERIDIN 2 YLMETHYL)INDOLE F 18; 3 QUINUCLIDINYL BENZILATE I 125; 4 FLUORODEPRENYL C 11; 4 IODODEXETIMIDE I 123; 4 IODOLEVETIMIDE I 123; 8 CHLORO 5 (7 BENZOFURANYL) 7 HYDROXY 3 METHYL 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPINE C 11; 8 METHYL 3 (4 TRIFLUOROMETHYLPHENYL) 8 AZABICYCLO[3.2.1]OCT 2 ENE C 11; 8 METHYL 3 [4 TRIFLUOROMETHOXYPHENYL] 8 AZABICYCLO[3.2.1]OCT 2 ENE C 11; CLOZAPINE; COCAINE C 11; CYCLOFOXY F 18; CYCLOFOXY H 3; DIHYDROTETRABENAZINE C 11; FLUORONORADRENALINE(2 AMINO 1 PHENYL 1 PROPANOL) F 18; KETAMINE C 11; METHYLPHENIDATE C 11; MIRTAZAPINE C 11; MUSCARINIC RECEPTOR BLOCKING AGENT; NICOTINE C 11; NICOTINIC RECEPTOR BLOCKING AGENT; RACLOPRIDE C 11; ROLIPRAM C 11; SELEGILINE C 11; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL C 11;

CHOLINERGIC SYSTEM; CONTINUOUS INFUSION; DOPAMINERGIC ACTIVITY; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG UPTAKE; ENANTIOMER; HUMAN; IN VIVO STUDY; NEUROIMAGING; NEUROTRANSMISSION; NONHUMAN; NORADRENERGIC SYSTEM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEREOCHEMISTRY;

ANIMALS; DIAGNOSTIC IMAGING; HUMANS; NEUROTRANSMITTER AGENTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, NEUROTRANSMITTER; STEREOISOMERISM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 34248592527     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2007.02.008     Document Type: Review

References (99)

1. Abi-Dargham A., Mawlawi O., Lombardo I., Gil R., Martinez D., Huang Y., Hwang D.R., Keilp J., Kochan L., Van Heertum R., Gorman J.M., and Laruelle M. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J. Neurosci. 22 (2002) 3708-3719
2. Aceto M.D., Martin B.R., and May E.L. Nicotine enantiomers: pharmacological and biochemical effects. In: Smith D.F. (Ed). CRC Handbook of Stereoisomers: Drugs in Psychopharmacology (1984), CRC Press, Inc, Boca Raton, Fl. 67-78
3. Andersen P.H., Grønvald F.C., Hohlweg R., Hansen L.B., Guddal E., Braestrup C., and Nielsen E.B. NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists. Eur. J. Pharmacol. 219 (1992) 45-52
4. Ariëns E.J. Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur. J. Clin. Pharmacol. 26 (1984) 663-668
5. Ariëns E.J. Stereochemistry: a source of problems in medicinal chemistry. Med. Res. Rev. 6 (1986) 451-466
6. Baker G.B., and Prior T.I. Stereochemistry and drug efficacy and development: relevance of chirality to antidepressant and antipsychotic drugs. Ann. Med. 34 (2002) 537-543
7. Barlow R. Enantiomers: how valid is Pfeiffer's rule?. Trends Pharmacol. Sci. 11 (1990) 148-150
8. Bauer D., Hamacher K., Bröer S., Pauleit D., Palm C., Zilles K., Coenen H.H., and Langen K.J. Preferred stereoselective brain uptake of d-serine-a modulator of glutamatergic neurotransmission. Nucl. Med. Biol. 32 (2005) 793-797
9. Baumann P., Zullino D., and Eap C. Enantiomers' potential in psychopharmacology-a critical analysis with special emphasis on the antidepressant escitalopram. Eur. Neuropsychopharmacol. 12 (2002) 433-444
10. Brocks D.R., and Mehvar R. Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs. Clin. Pharmacokinet. 42 (2003) 1359-1382
11. Brøsen K., and Naranjo C.A. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur. Neuropsychopharmacol. 11 (2001) 275-283
12. 18F]fluoromethyl)-(+)-McN5652. Synapse 47 (2003) 143-151
13. 18F cyclofoxy with PET. J. Cereb. Blood Flow Metab. 9 (1989) S16
14. Chou Y.H., Halldin C., and Farde L. Clozapine binds preferentially to cortical D1-like dopamine receptors in the primate brain: a PET study. Psychopharmacology (Berl) 185 (2006) 29-35
15. Christensen M.K., and Smith D.F. Antinociceptive effects of the stereoisomers of nicotine given intrathecally in spinal rats. J. Neural Transm. Gen. Sect. 80 (1990) 189-194
16. Cortes R., Probst A., and Palacios J.M. Quantitative light microscopic autoradiographic localization of cholinergic muscarinic receptors in the human brain: forebrain. Neuroscience 20 (1987) 65-107
17. de Boer T.H., Maura G., Raiteri M., de Vos C.J., Wieringa J., and Pinder R.M. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology 27 (1988) 399-408
18. Dewey W.L., Martin B.R., and May E.L. Cannabinoid stereoisomers: pharmacological effects. In: Smith D.F. (Ed). CRC Handbook of Stereoisomers: Drugs in Psychopharmacology (1984), CRC Press, Inc., Boca Raton, Fl. 317-326
19. Ding Y.S., and Fowler J.S. Highlights of PET studies on chiral radiotracers and drugs at Brookhaven. Drug Dev. Res. 59 (2003) 227-239
20. 18F]fluorodopamine in baboons: heart uptake, metabolism and the effect of desipramine. J. Nucl. Med. 34 (1993) 619-629
21. Ding Y.S., Fowler J.S., Volkow N.D., Logan J., Gatley S.J., and Sugano Y. Carbon-11-d-threo-methylphenidate binding to dopamine transporter in baboon brain. J. Nucl. Med. 36 (1995) 2298-2305
22. 11C]d-threo and l-threo-methylphenidate in the human and baboon brain. Psychopharmacology (Berl) 131 (1997) 71-78
23. Ding Y.S., Lin K.S., Garza V., Carter P., Alexoff D., Logan J., Shea C., Xu Y., and King P. Evaluation of a new norepinephrine transporter PET ligand in baboons, both in brain and peripheral organs. Synapse 50 (2003) 345-352
24. Ding Y.S., Gatley S.J., Thanos P.K., Shea C., Garza V., Xu Y., Carter P., King P., Warner D., Taintor N.B., Park D.J., Pyatt B., Fowler J.S., and Volkow N.D. Brain kinetics of methylphenidate (Ritalin) enantiomers after oral administration. Synapse 53 (2004) 168-175
25. Draskoczy P.R., and Trendelenburg U. The uptake of l- and d-norepinephrine by the isolated perfused rabbit heart in relation to the stereospecificity of the sensitizing action of cocaine. J. Pharmacol. Exp. Ther. 159 (1968) 66-73
26. Eckelman W.C., Eng R., Rzeszotarski W.J., Gibson R.E., Francis B., and Reba R.C. Use of 3-quinuclidinyl 4-iodobenzilate as a receptor binding radiotracer. J. Nucl. Med. 26 (1985) 637-642
27. Farde L., Pauli S., Hall H., Eriksson L., Halldin C., Högberg T., Nilsson L., Sjögren I., and Stone-Elander S. Stereoselective binding of 11C-raclopride in living human brain-a search for extrastriatal central D2-dopamine receptors by PET. Psychopharmacology (Berl) 94 (1988) 471-478
28. Fava M., Rush A.J., Trivedi M.H., Nierenberg A.A., Thase M.E., Sackeim H.A., Quitkin F.M., Wisniewski S., Lavori P.W., Rosenbaum J.F., and Kupfer D.J. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr. Clin. North Am. 26 (2003) 457-494
29. 11C-labeled suicide inactivators and PET. Science 235 (1987) 481-485
30. 11C]Rolipram-PET. NeuroImage 26 (2005) 1201-1210
31. Gatley S.J., MacGregor R.R., Fowler J.S., Wolf A.P., Dewey S.L., and Schlyer D.J. Rapid stereoselective hydrolysis of (+)-cocaine in baboon plasma prevents its uptake in the brain: implications for behavioral studies. J. Neurochem. 54 (1990) 720-723
32. Gibson R.E., Schneidau T.A., Cohen V.I., Sood V., Ruch J., Melograna J., Eckelman W.C., and Reba R.C. In vitro and in vivo characteristics of [iodine-125] 3-(R)-quinuclidinyl (S)-4-iodobenzilate. J. Nucl. Med. 30 (1989) 1079-1087
33. Haddjeri N., Blier P., and de Montigny C. Effect of the alpha-2 adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain. J. Pharmacol. Exp. Ther. 277 (1996) 861-871
34. 3H-raclopride. J. Neural Transm. 73 (1988) 7-21
35. 1-dopamine receptors. J. Nucl. Med. 39 (1998) 2061-2068
36. Hanna G.M., and Lau-Cam C.A. Determination of the optical purity and absolute configuration of threo-methylphenidate by proton nuclear magnetic resonance spectroscopy with chiral solvating agent. J. Pharm. Biomed. Anal. 11 (1993) 665-670
37. 11C]ketamine in the rhesus monkey studied by positron emission tomography (PET). Nucl. Med. Biol. 21 (1994) 927-934
38. Horn A.S. Basic terms in stereochemistry. In: Smith D.F. (Ed). CRC Handbook of Stereoisomers: Drugs in Psychopharmacology (1984), CRC Press, Inc., Boca Raton, Fl. 1-9
39. 11C]McN5652. J. Cereb. Blood Flow Metab. 22 (2002) 490-501
40. Katz J.L., Tirelli E., and Witkin J.M. Stereoselective effects of cocaine. Behav. Pharmacol. 1 (1990) 347-353
41. Kawai R., Sawada Y., Channing M., Dunn B., Newman A.H., Rice K.C., and Blasberg R.G. Kinetic analysis of the opiate antagonist cyclofoxy in rat brain: simultaneous infusion of active and inactive enantiomers. J. Pharmacol. Exp. Ther. 255 (1990) 826-835
42. Kawai R., Sawada Y., Channing M., Newman A.H., Rice K.C., and Blasberg R.G. BBB transport and rapid tissue binding of cyclofoxy: comparison of active and inactive enantiomers. Am. J. Physiol. 259 (1990) H1278-H1287
43. Kilbourn M., Lee L., Vander B.T., Jewett D., and Frey K. Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. Eur. J. Pharmacol. 278 (1995) 249-252
44. 11C]dihydrotetrabenazine. J. Cereb. Blood Flow Metab. 19 (1999) 1376-1384
45. Kurono M., Fujii A., Murata M., Fujitani B., and Negoro T. Stereospecific recognition of a spirosuccinimide type aldose reductase inhibitor (AS-3201) by plasma proteins: a significant role of specific binding by serum albumin in the improved potency and stability. Biochem. Pharmacol. 71 (2006) 338-353
46. 3H]dexetimide to brain muscarinic receptors. J. Neurochem. 32 (1979) 421-427
47. Lammertsma A.A. Radioligand studies: imaging and quantitative analysis. Eur. Neuropsychopharmacol. 12 (2002) 513-516
48. 11C]raclopride studies. J. Cereb. Blood Flow Metab. 16 (1996) 42-52
49. 18F]fluoro-proline at the blood-brain barrier. J. Cereb. Blood Flow Metab. 25 (2005) 607-616
50. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J. Cereb. Blood Flow Metab. 20 (2000) 423-451
51. Laruelle M., and Maloteaux J.M. Regional distribution of serotonergic pre- and postsynaptic markers in human brain. Acta Psychiatr. Scand., Suppl. 350 (1989) 56-59
52. 3H]paroxetine binding, a marker of serotonin uptake sites. Biol. Psychiatry 24 (1988) 299-309
53. 123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 13 (1993) 295-309
54. Laruelle M., Slifstein M., and Huang Y. Positron emission tomography: imaging and quantification of neurotransporter availability. Methods 27 (2002) 287-299
55. Le Foll B., and Goldberg S.R. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J. Pharmacol. Exp. Ther. 312 (2005) 875-883
56. Lodge D., and Johnson K.M. Noncompetitive excitatory amino acid receptor antagonists. Trends Pharmacol. Sci. 11 (1990) 81-86
57. 11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. Nucl. Med. Biol. 30 (2003) 747-751
58. Luurtsema G., de Lange E.C., Lammertsma A.A., and Franssen E.J. Transport across the blood-brain barrier: stereoselectivity and PET-tracers. Mol. Imaging Biol. 6 (2004) 306-318
59. Mansfield P., Henry D., and Tonkin A. Single-enantiomer drugs: elegant science, disappointing effects. Clin. Pharmacokinet. 43 (2004) 287-290
60. 123I]4-iodolevetimide. J. Cereb. Blood Flow Metab. 12 (1992) 562-570
61. 11C]-nicotine in the brains of rhesus monkey. An attempt to study nicotinic receptors in vivo. J. Neural Transm., Parkinson's Dis. Dement. Sect. 1 (1989) 195-205
62. 11C-nicotine in brain of Alzheimer patients as visualized by positron emission tomography. J. Neural Transm., Parkinson's Dis. Dement. Sect. 2 (1990) 215-224
63. Nordberg A., Lilja A., Lundqvist H., Hartvig P., Amberla K., Viitanen M., Warpman U., Johansson M., Hellström-Lindahl E., Bjurling P., Fasth K.-J., Långström B., and Winblad B. Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography. Neurobiol. Aging 13 (1992) 747-758
64. 11C]nicotine in the human brain: difficulties in visualizing specific receptor binding in vivo. Psychopharmacology (Berl) 115 (1994) 31-36
65. 2 receptor occupancy studies and clinical response. Br. J. Psychiatry Suppl. 29 (1996) 40-44
66. 3H]cyclofoxy retention in rat brain after in vivo injection corresponds to the in vitro opiate receptor distribution. Brain Res. 402 (1987) 275-286
67. Øye I., Paulsen O., and Maurset A. Effects of ketamine on sensory perception: evidence for a role of N-methyl-d-aspartate receptors. J. Pharmacol. Exp. Ther. 260 (1992) 1209-1213
68. 11C]S(+)-rolipram in vitro and in vivo, and their use as PET radiotracers for the quantificative assay of PDE4. Synapse 55 (2005) 270-279
69. 11C]McN 5652. J. Nucl. Med. 41 (2000) 1465-1477
70. Patrick K.S., Caldwell R.W., Ferris R.M., and Breese G.R. Pharmacology of the enantiomers of threo-methylphenidate. J. Pharmacol. Exp. Ther. 241 (1987) 152-158
71. Pfeiffer C.C. Optical isomerism and pharmacological action, a generalization. Science 124 (1956) 29-31
72. 11C-methyl]-4-fluorodeprenyl and positron emission tomography studies in baboon brain. J. Med. Chem. 33 (1990) 2015-2019
73. Portoghese P.S. Relationships between stereostructure and pharmacological activities. Annu. Rev. Pharmacol. 10 (1970) 51-76
74. Ritz M.C., Lamb R.J., Goldberg S.R., and Kuhar M.J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237 (1987) 1219-1223
75. 125I]-4-iodolevetimide. Neuropharmacology 32 (1993) 1441-1443
76. 125I]iodobenzilate transport and specific binding to muscarinic acetylcholine receptor in rat brain in vivo: implications for human studies. J. Cereb. Blood Flow Metab. 10 (1990) 781-807
77. Scanley B.E., Baldwin R.M., Laruelle M., al Tikriti M.S., Zea-Ponce Y., Zoghbi S., Giddings S.S., Charney D.S., Hoffer P.B., and Wang S. Active and inactive enantiomers of 2β-carbomethoxy-3β-(4-iodophenyl)tropane: comparison using homogenate binding and single photon emission computed tomographic imaging. Mol. Pharmacol. 45 (1994) 136-141
78. 3H]paroxetine. J. Neurochem. 52 (1989) 1605-1612
79. Scheffel U., Szabo Z., Mathews W.B., Finley P.A., Dannals R.F., Ravert H.T., Szabo K., Yuan J., and Ricaurte G.A. In vivo detection of short- and long-term MDMA neurotoxicity-a positron emission tomography study in the living baboon brain. Synapse 29 (1998) 183-192
80. 11C]MeNER. Nucl. Med. Biol. 30 (2003) 707-714
81. Schou M., Halldin C., Sovago J., Pike V.W., Hall H., Gulyas B., Mozley P.D., Dobson D., Shchukin E., Innis R.B., and Farde L. PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain. Synapse 53 (2004) 57-67
82. Shank R.P., Vaught J.L., Pelley K.A., Setler P.E., McComsey D.F., and Maryanoff B.E. McN-5652: a highly potent inhibitor of serotonin uptake. J. Pharmacol. Exp. Ther. 247 (1988) 1032-1038
83. +-oscillations in cultured hippocampal neurons. Anesth. Analg. 100 (2005) 1660-1666
84. Smith D.F. Handbook of Stereoisomers. Drugs in Psychopharmacology (1984), CRC Press Inc., Boca Raton, Fl
85. Smith D.F. The stereoselectivity of serotonin uptake in brain tissue and blood platelets: the topography of the serotonin uptake area. Neurosci. Biobehav. Rev. 10 (1986) 37-46
86. Smith D.F., Jensen P.N., Poulsen S.H., Mikkelsen E.O., Elbaz E., and Glaser R. Effects of pyrroloisoquinoline enantiomers ((+)- and (-)-McN-5652-Z) on behavioral and pharmacological serotonergic mechanisms in rats. Eur. J. Pharmacol. 196 (1991) 85-92
87. Smith D.F., Gee A.D., Hansen S.B., Moldt P., Nielsen E.O., Scheel-Kruger J., and Gjedde A. Uptake and distribution of a new SSRI, NS2381, studied by PET in living porcine brain. Eur. Neuropsychopharmacol. 9 (1999) 351-359
88. 11C]NS2456 and its enantiomers as selective serotonin reuptake radiotracers for PET. Nucl. Med. Biol. 28 (2001) 265-270
89. Smith D.F., Marthi K., Munk O.L., Cumming P., Hansen S.B., and Jakobsen S. PET neuroimaging of [(11)C]mirtazapine enantiomers in pigs. Eur. Neuropsychopharmacol. 16 (2006) 350-357
90. Stjarne L., and von Euler U.S. Sterospecificity of amine uptake mechanism in nerve granules. J. Pharmacol. Exp. Ther. 150 (1965) 335-340
91. 11C](+)McN5652. Synapse 20 (1995) 37-43
92. 11C]McN5652. J. Cereb. Blood Flow Metab. 15 (1995) 798-805
93. Szabo Z., Kao P.F., Mathews W.B., Ravert H.T., Musachio J.L., Scheffel U., and Dannals R.F. Positron emission tomography of 5-HT reuptake sites in the human brain with C-11 McN5652 extraction of characteristic images by artificial neural network analysis. Behav. Brain Res. 73 (1996) 221-224
94. Vardy E.R., Hussain I., and Hooper N.M. Emerging therapeutics for Alzheimer's disease. Expert Rev. Neurother. 6 (2006) 695-704
95. Wachtel H. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors. Neuropharmacology 22 (1983) 267-272
96. Walle T., and Walle U.K. Pharmacokinetic parameters obtained with racemates. Trends Pharmacol. Sci. 7 (1986) 155-158
97. Willis P.G., Pavlova O.A., Chefer S.I., Vaupel D.B., Mukhin A.G., and Horti A.G. Synthesis and structure-activity relationship of a novel series of aminoalkylindoles with potential for imaging the neuronal cannabinoid receptor by positron emission tomography. J. Med. Chem. 48 (2005) 5813-5822
98. Wilson A.A., Johnson D.P., Mozley D., Hussey D., Ginovart N., Nobrega J., Garcia A., Meyer J., and Houle S. Synthesis and in vivo evaluation of novel radiotracers for the in vivo imaging of the norepinephrine transporter. Nucl. Med. Biol. 30 (2003) 85-92
99. Zheng G., Dwoskin L.P., and Crooks P.A. Vesicular monoamine transporter 2: role as a novel target for drug development. AAPS J 8 (2006) E682-E692